Cochrane · systematic review · CD006803
Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus
Gurusamy, KS, Tsochatzis, E, Toon, CD, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 9 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antiviral therapy for recurrent liver graft infection with hepatitis C virus (mortality)
Population: Participants with recurrent liver graft infection with hepatitis C virus.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Peg interferon vs.control | RR 0.48 [0.05, 5.09] | 1 study · 65 participants | Very low Downgraded: risk of bias |
Peg interferon plus ribavirin vs.control | RR 3 [0.13, 70.53] | 1 study · 54 participants | Very low Downgraded: risk of bias |
Ribavirin plus peg interferon vs.peg interferon | RR 0.5 [0.05, 5.2] | 2 studies · 98 participants | Very low Downgraded: risk of bias |
Interferon vs.control | RR 1.67 [0.08, 33.75] | 1 study · 12 participants | Very low Downgraded: risk of bias |
Interferon plus ribavirin vs.control | RR 0.29 [0.01, 6.74] | 1 study · 52 participants | Very low Downgraded: risk of bias |
Ribavirin vs.interferon | no estimate extracted | 1 study · 30 participants | Very low Downgraded: risk of bias |
Ribavirin vs.placebo | no estimate extracted | 1 study · 77 participants | Very low Downgraded: risk of bias |
Antiviral therapy for recurrent liver graft infection with hepatitis C virus (retransplantation)
Population: Participants with recurrent liver graft infection with hepatitis C virus.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Retransplantation after start of therapy ‐ ribavirin vs.placebo | no estimate extracted | 1 study · 77 participants | Very low Downgraded: risk of bias |
Retransplantation after start of therapy ‐ interferon vs.control | RR 1.67 [0.08, 33.75] | 1 study · 12 participants | Very low Downgraded: risk of bias |